Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020
| Autor: | Flamand, Claude, Alves Sarmento, Christelle, Enfissi, Antoine, Bailly, Sarah, Beillard, Emmanuel, Gaillet, Mélanie, Michaud, Céline, Servas, Véronique, Clement, Nathalie, Perilhou, Anaïs, Carage, Thierry, Musso, Didier, Carod, Jean-François, Eustache, Stéphanie, Tourbillon, Céline, Boizon, Elodie, James, Samantha, Djossou, Félix, Salje, Henrik, Cauchemez, Simon, Rousset, Dominique |
|---|---|
| Předmět: | |
| Popis: | Funder: National Research Agency Funder: Regional Health Agency of French Guiana Funder: Institut Pasteur Urgence COVID-19 fundraising BACKGROUND: While Latin America has been heavily affected by the pandemic, only a few seroprevalence studies have been conducted there during the first epidemic wave in the first half of 2020. METHODOLOGY/PRINCIPAL FINDINGS: A cross-sectional survey was performed between 15 July 2020 and 23 July 2020 among individuals who visited 4 medical laboratories or 5 health centers for routine screening or clinical management, with the exception of symptomatic suggestive cases of covid-19. Samples were screened for the presence of anti-SARS-CoV-2 IgG directed against domain S1 of the SARS-CoV-2 spike protein using the anti-SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA) from Euroimmun. CONCLUSIONS/SIGNIFICANCE: The overall seroprevalence was 15.4% [9.3%-24.4%] among 480 participants, ranging from 4.0% to 25.5% across the different municipalities. The seroprevalence did not differ according to gender (p = 0.19) or age (p = 0.51). Among SARS-CoV-2 positive individuals, we found that 24.6% [11.5%-45.2%] reported symptoms consistent with COVID-19. Our findings revealed high levels of infection across the territory but a low number of resulting deaths, which can be explained by French Guiana's young population structure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|